LRP4 and myasthenia gravis: Myasthenia gravis (MG) is a rare autoimmune disease characterized by the production of autoantibodies that target the nicotinic acetylcholine receptors (AChRs) or functionally related proteins (MuSK and LRP4), which disrupt neuromuscular transmission causing pronounced skeletal muscle weakness [1].